_id
690db659ccc777a4e85d0e22
Ticker
BDRX
Name
Biodexa Pharmaceticals
Exchange
NASDAQ
Address
1 Caspian Point, Cardiff, United Kingdom, CF10 4DQ
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.biodexapharma.com
Description
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Last Close
2.29
Volume
120170
Current Price
2.2458
Change
0.0058
Last Updated
2026-01-20T16:23:18.026Z
Image
data:image/webp;base64,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
Ipo Date
2015-12-07T00:00:00.000Z
Market Cap
1878882
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.07750000000000003
Sentiment Sources
4
Rating
5
Target Price
178.3005
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
-
Cost Of Revenue
1665000
Gross Profit
-1665000
Operating Expenses
2351000
Operating Income
-4016000
Interest Expense
100000
Pretax Income
-3971000
Net Income
-3806000
Eps
-152240
Dividends Per Share
-
Shares Outstanding
838787
Income Tax Expense
165000
EBITDA
-3945000
Operating Margin
-
Total Other Income Expense Net
45000
Cash
4035999
Short Term Investments
-
Receivables
4494000
Inventories
-
Total Current Assets
8992000
Property Plant Equipment
187000
Total Assets
14824000
Payables
1414000
Short Term Debt
501000
Long Term Debt
-
Total Liabilities
3388000
Equity
11436000
Bs_currency_symbol
GBP
Depreciation
140000
Change In Working Capital
2047000
Cash From Operations
-3304000
Capital Expenditures
2000
Cash From Investing
-339000
Cash From Financing
6010000
Net Change In Cash
4035999
Cf_currency_symbol
-
PE
-
PB
0.000004909496327387198
ROE
-33.28086743616649
ROA
-25.674581759309227
FCF
-3306000
Fcf Percent
-
Piotroski FScore
1
Health Score
42
Deep Value Investing Score
6.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
8
Quality Investing Score
2.5
Value Investing Score
5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
1665000
Quarters > 0 > income Statement > gross Profit
-1665000
Quarters > 0 > income Statement > operating Expenses
2351000
Quarters > 0 > income Statement > operating Income
-4016000
Quarters > 0 > income Statement > interest Expense
100000
Quarters > 0 > income Statement > pretax Income
-3971000
Quarters > 0 > income Statement > net Income
-3806000
Quarters > 0 > income Statement > eps
-152240
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
25
Quarters > 0 > income Statement > income Tax Expense
165000
Quarters > 0 > income Statement > EBITDA
-3945000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
45000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
4035999
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
4494000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
8992000
Quarters > 0 > balance Sheet > property Plant Equipment
187000
Quarters > 0 > balance Sheet > total Assets
14824000
Quarters > 0 > balance Sheet > payables
1414000
Quarters > 0 > balance Sheet > short Term Debt
501000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
3388000
Quarters > 0 > balance Sheet > equity
11436000
Quarters > 0 > balance Sheet > currency_symbol
GBP
Quarters > 0 > cash Flow > net Income
-3806000
Quarters > 0 > cash Flow > depreciation
140000
Quarters > 0 > cash Flow > change In Working Capital
2047000
Quarters > 0 > cash Flow > cash From Operations
-3304000
Quarters > 0 > cash Flow > capital Expenditures
2000
Quarters > 0 > cash Flow > cash From Investing
-339000
Quarters > 0 > cash Flow > cash From Financing
6010000
Quarters > 0 > cash Flow > net Change In Cash
4035999
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-152240
Quarters > 0 > ratios > PB
0.000004909496327387198
Quarters > 0 > ratios > ROE
-33.28086743616649
Quarters > 0 > ratios > ROA
-25.674581759309227
Quarters > 0 > ratios > FCF
-3306000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
42
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
3248000
Quarters > 1 > income Statement > gross Profit
-3248000
Quarters > 1 > income Statement > operating Expenses
1728000
Quarters > 1 > income Statement > operating Income
-4976000
Quarters > 1 > income Statement > interest Expense
37000
Quarters > 1 > income Statement > pretax Income
-2546000
Quarters > 1 > income Statement > net Income
-2421000
Quarters > 1 > income Statement > eps
-3.90784522931352
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
619523
Quarters > 1 > income Statement > income Tax Expense
-125000
Quarters > 1 > income Statement > EBITDA
-4927000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2430000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1669000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
715000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
8810000
Quarters > 1 > balance Sheet > property Plant Equipment
324000
Quarters > 1 > balance Sheet > total Assets
14780000
Quarters > 1 > balance Sheet > payables
707000
Quarters > 1 > balance Sheet > short Term Debt
609000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
6458000
Quarters > 1 > balance Sheet > equity
8322000
Quarters > 1 > balance Sheet > currency_symbol
GBP
Quarters > 1 > cash Flow > net Income
-2421000
Quarters > 1 > cash Flow > depreciation
118000
Quarters > 1 > cash Flow > change In Working Capital
-2438000
Quarters > 1 > cash Flow > cash From Operations
-7454000
Quarters > 1 > cash Flow > capital Expenditures
774000
Quarters > 1 > cash Flow > cash From Investing
156000
Quarters > 1 > cash Flow > cash From Financing
3912000
Quarters > 1 > cash Flow > net Change In Cash
-5055000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-3.90784522931352
Quarters > 1 > ratios > PB
0.16718634383561645
Quarters > 1 > ratios > ROE
-29.09156452775775
Quarters > 1 > ratios > ROA
-16.380243572395127
Quarters > 1 > ratios > FCF
-8228000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
37
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
2189000
Quarters > 2 > income Statement > gross Profit
-2189000
Quarters > 2 > income Statement > operating Expenses
4223000
Quarters > 2 > income Statement > operating Income
-4223000
Quarters > 2 > income Statement > interest Expense
49000
Quarters > 2 > income Statement > pretax Income
-3433000
Quarters > 2 > income Statement > net Income
-3308000
Quarters > 2 > income Statement > eps
-133.4947538337369
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
24780
Quarters > 2 > income Statement > income Tax Expense
-125000
Quarters > 2 > income Statement > EBITDA
-3248000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
790000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
5055000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
1922000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
7524000
Quarters > 2 > balance Sheet > property Plant Equipment
436000
Quarters > 2 > balance Sheet > total Assets
13968000
Quarters > 2 > balance Sheet > payables
1689000
Quarters > 2 > balance Sheet > short Term Debt
348000
Quarters > 2 > balance Sheet > long Term Debt
208000
Quarters > 2 > balance Sheet > total Liabilities
5241000
Quarters > 2 > balance Sheet > equity
8727000
Quarters > 2 > balance Sheet > currency_symbol
GBP
Quarters > 2 > cash Flow > net Income
-3308000
Quarters > 2 > cash Flow > depreciation
136000
Quarters > 2 > cash Flow > change In Working Capital
-1298000
Quarters > 2 > cash Flow > cash From Operations
-4807000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-754000
Quarters > 2 > cash Flow > cash From Financing
4645000
Quarters > 2 > cash Flow > net Change In Cash
5055000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-133.4947538337369
Quarters > 2 > ratios > PB
0.006376867652114129
Quarters > 2 > ratios > ROE
-37.90535120889194
Quarters > 2 > ratios > ROA
-23.682703321878577
Quarters > 2 > ratios > FCF
-4807000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
37
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
1094500
Quarters > 3 > income Statement > gross Profit
-1094500
Quarters > 3 > income Statement > operating Expenses
1017000
Quarters > 3 > income Statement > operating Income
-2111500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1716500
Quarters > 3 > income Statement > net Income
-1654000
Quarters > 3 > income Statement > eps
-5.041453304072178
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
328080
Quarters > 3 > income Statement > income Tax Expense
62500
Quarters > 3 > income Statement > EBITDA
-2077500
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
395000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
5055000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
1922000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
7524000
Quarters > 3 > balance Sheet > property Plant Equipment
436000
Quarters > 3 > balance Sheet > total Assets
13968000
Quarters > 3 > balance Sheet > payables
1689000
Quarters > 3 > balance Sheet > short Term Debt
174000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
5241000
Quarters > 3 > balance Sheet > equity
8727000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-1654000
Quarters > 3 > cash Flow > depreciation
68000
Quarters > 3 > cash Flow > change In Working Capital
-649000
Quarters > 3 > cash Flow > cash From Operations
-2403500
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
2322500
Quarters > 3 > cash Flow > net Change In Cash
-458000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-5.041453304072178
Quarters > 3 > ratios > PB
0.08442787487108971
Quarters > 3 > ratios > ROE
-18.95267560444597
Quarters > 3 > ratios > ROA
-11.841351660939289
Quarters > 3 > ratios > FCF
-2403500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
37
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
5437000
Annuals > 0 > income Statement > gross Profit
-5437000
Annuals > 0 > income Statement > operating Expenses
3762000
Annuals > 0 > income Statement > operating Income
-9199000
Annuals > 0 > income Statement > interest Expense
165000
Annuals > 0 > income Statement > pretax Income
-5979000
Annuals > 0 > income Statement > net Income
-5729000
Annuals > 0 > income Statement > eps
-9.247437141155373
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
619523
Annuals > 0 > income Statement > income Tax Expense
-250000
Annuals > 0 > income Statement > EBITDA
-9082000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
3220000
Annuals > 0 > income Statement > currency_symbol
GBP
Annuals > 0 > balance Sheet > cash
1669000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
715000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
8810000
Annuals > 0 > balance Sheet > property Plant Equipment
324000
Annuals > 0 > balance Sheet > total Assets
14780000
Annuals > 0 > balance Sheet > payables
707000
Annuals > 0 > balance Sheet > short Term Debt
609000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
6458000
Annuals > 0 > balance Sheet > equity
8322000
Annuals > 0 > balance Sheet > currency_symbol
GBP
Annuals > 0 > cash Flow > net Income
-5729000
Annuals > 0 > cash Flow > depreciation
254000
Annuals > 0 > cash Flow > change In Working Capital
-3736000
Annuals > 0 > cash Flow > cash From Operations
-12261000
Annuals > 0 > cash Flow > capital Expenditures
774000
Annuals > 0 > cash Flow > cash From Investing
-598000
Annuals > 0 > cash Flow > cash From Financing
8557000
Annuals > 0 > cash Flow > net Change In Cash
-4302000
Annuals > 0 > cash Flow > currency_symbol
GBP
Annuals > 0 > ratios > PE
-9.247437141155373
Annuals > 0 > ratios > PB
0.16718634383561645
Annuals > 0 > ratios > ROE
-68.84162460946888
Annuals > 0 > ratios > ROA
-38.76184032476319
Annuals > 0 > ratios > FCF
-13035000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
29
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
381000
Annuals > 1 > income Statement > cost Of Revenue
4067000
Annuals > 1 > income Statement > gross Profit
-3686000
Annuals > 1 > income Statement > operating Expenses
4328000
Annuals > 1 > income Statement > operating Income
-8014000
Annuals > 1 > income Statement > interest Expense
41000
Annuals > 1 > income Statement > pretax Income
-7485000
Annuals > 1 > income Statement > net Income
-7079000
Annuals > 1 > income Statement > eps
-22909.385113268607
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
309
Annuals > 1 > income Statement > income Tax Expense
-406000
Annuals > 1 > income Statement > EBITDA
-7161000
Annuals > 1 > income Statement > operating Margin
-2103.412073490814
Annuals > 1 > income Statement > total Other Income Expense Net
529000
Annuals > 1 > income Statement > currency_symbol
GBP
Annuals > 1 > balance Sheet > cash
5971000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
704000
Annuals > 1 > balance Sheet > inventories
-704000
Annuals > 1 > balance Sheet > total Current Assets
7030000
Annuals > 1 > balance Sheet > property Plant Equipment
571000
Annuals > 1 > balance Sheet > total Assets
10542000
Annuals > 1 > balance Sheet > payables
314000
Annuals > 1 > balance Sheet > short Term Debt
169000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
5864000
Annuals > 1 > balance Sheet > equity
4678000
Annuals > 1 > balance Sheet > currency_symbol
GBP
Annuals > 1 > cash Flow > net Income
-7079000
Annuals > 1 > cash Flow > depreciation
283000
Annuals > 1 > cash Flow > change In Working Capital
-49000
Annuals > 1 > cash Flow > cash From Operations
-6826000
Annuals > 1 > cash Flow > capital Expenditures
263000
Annuals > 1 > cash Flow > cash From Investing
-265000
Annuals > 1 > cash Flow > cash From Financing
10226000
Annuals > 1 > cash Flow > net Change In Cash
3135000
Annuals > 1 > cash Flow > currency_symbol
GBP
Annuals > 1 > ratios > PE
-22909.385113268607
Annuals > 1 > ratios > PB
0.00014834377939290297
Annuals > 1 > ratios > ROE
-151.3253527148354
Annuals > 1 > ratios > ROA
-67.1504458357048
Annuals > 1 > ratios > FCF
-7089000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-18.606299212598426
Annuals > 1 > health Score
23
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
699000
Annuals > 2 > income Statement > cost Of Revenue
5111000
Annuals > 2 > income Statement > gross Profit
-4412000
Annuals > 2 > income Statement > operating Expenses
4520000
Annuals > 2 > income Statement > operating Income
-8932000
Annuals > 2 > income Statement > interest Expense
53000
Annuals > 2 > income Statement > pretax Income
-8488000
Annuals > 2 > income Statement > net Income
-7656000
Annuals > 2 > income Statement > eps
-510400
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
15
Annuals > 2 > income Statement > income Tax Expense
-832000
Annuals > 2 > income Statement > EBITDA
-8261000
Annuals > 2 > income Statement > operating Margin
-1277.8254649499286
Annuals > 2 > income Statement > total Other Income Expense Net
444000
Annuals > 2 > income Statement > currency_symbol
GBP
Annuals > 2 > balance Sheet > cash
2836000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
329000
Annuals > 2 > balance Sheet > inventories
1
Annuals > 2 > balance Sheet > total Current Assets
4688000
Annuals > 2 > balance Sheet > property Plant Equipment
831000
Annuals > 2 > balance Sheet > total Assets
5525000
Annuals > 2 > balance Sheet > payables
339000
Annuals > 2 > balance Sheet > short Term Debt
161000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
2363000
Annuals > 2 > balance Sheet > equity
3162000
Annuals > 2 > balance Sheet > currency_symbol
GBP
Annuals > 2 > cash Flow > net Income
-7656000
Annuals > 2 > cash Flow > depreciation
343000
Annuals > 2 > cash Flow > change In Working Capital
520000
Annuals > 2 > cash Flow > cash From Operations
-7048000
Annuals > 2 > cash Flow > capital Expenditures
62000
Annuals > 2 > cash Flow > cash From Investing
-220000
Annuals > 2 > cash Flow > cash From Financing
47000
Annuals > 2 > cash Flow > net Change In Cash
-7221000
Annuals > 2 > cash Flow > currency_symbol
GBP
Annuals > 2 > ratios > PE
-510400
Annuals > 2 > ratios > PB
0.000010653700189753321
Annuals > 2 > ratios > ROE
-242.12523719165085
Annuals > 2 > ratios > ROA
-138.57013574660633
Annuals > 2 > ratios > FCF
-7110000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-10.17167381974249
Annuals > 2 > health Score
29
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
578000
Annuals > 3 > income Statement > cost Of Revenue
4654000
Annuals > 3 > income Statement > gross Profit
-4076000
Annuals > 3 > income Statement > operating Expenses
2922000
Annuals > 3 > income Statement > operating Income
-6998000
Annuals > 3 > income Statement > interest Expense
44000
Annuals > 3 > income Statement > pretax Income
-6106000
Annuals > 3 > income Statement > net Income
-5460000
Annuals > 3 > income Statement > eps
-364000
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
15
Annuals > 3 > income Statement > income Tax Expense
-646000
Annuals > 3 > income Statement > EBITDA
-5659000
Annuals > 3 > income Statement > operating Margin
-1210.7266435986157
Annuals > 3 > income Statement > total Other Income Expense Net
892000
Annuals > 3 > income Statement > currency_symbol
GBP
Annuals > 3 > balance Sheet > cash
10057000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
33000
Annuals > 3 > balance Sheet > inventories
1
Annuals > 3 > balance Sheet > total Current Assets
11761000
Annuals > 3 > balance Sheet > property Plant Equipment
1152000
Annuals > 3 > balance Sheet > total Assets
12913000
Annuals > 3 > balance Sheet > payables
485000
Annuals > 3 > balance Sheet > short Term Debt
146000
Annuals > 3 > balance Sheet > long Term Debt
0
Annuals > 3 > balance Sheet > total Liabilities
2460531
Annuals > 3 > balance Sheet > equity
10452469
Annuals > 3 > balance Sheet > currency_symbol
GBP
Annuals > 3 > cash Flow > net Income
-5460000
Annuals > 3 > cash Flow > depreciation
403000
Annuals > 3 > cash Flow > change In Working Capital
-617000
Annuals > 3 > cash Flow > cash From Operations
-6008000
Annuals > 3 > cash Flow > capital Expenditures
320000
Annuals > 3 > cash Flow > cash From Investing
-278000
Annuals > 3 > cash Flow > cash From Financing
8805000
Annuals > 3 > cash Flow > net Change In Cash
2511000
Annuals > 3 > cash Flow > currency_symbol
GBP
Annuals > 3 > ratios > PE
-364000
Annuals > 3 > ratios > PB
0.0000032228749016141544
Annuals > 3 > ratios > ROE
-52.23646202634038
Annuals > 3 > ratios > ROA
-42.282970649732825
Annuals > 3 > ratios > FCF
-6328000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-10.948096885813149
Annuals > 3 > health Score
34
Valuation > metrics > PE
-152240
Valuation > metrics > PB
0.000004909496327387198
Valuation > final Score
70
Valuation > verdict
100.0% Undervalued
Profitability > metrics > ROE
-33.28086743616649
Profitability > metrics > ROA
-42.32651245551601
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2962574326687653
Risk > metrics > Interest Coverage
-40.16
Risk > final Score
-101
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.69556135770235
Liquidity > metrics > Quick Ratio
4.69556135770235
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-490
Prev Risks > 1
-297
Prev Risks > 2
25
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:28:15.048Z
Earnings History > 0 > period
2025-06-30
Earnings History > 0 > report Date
2025-09-12
Earnings History > 0 > date
2025-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-15.06
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-15.06
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-03-31
Earnings History > 1 > report Date
2025-04-11
Earnings History > 1 > date
2025-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-36.54
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-36.54
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2022-09-30
Earnings History > 2 > report Date
2022-11-30
Earnings History > 2 > date
2022-09-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
0
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2022-06-30
Earnings History > 3 > report Date
2022-09-14
Earnings History > 3 > date
2022-06-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
0
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2022-03-31
Earnings History > 4 > report Date
2022-04-26
Earnings History > 4 > date
2022-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
0
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2021-09-30
Earnings History > 5 > report Date
2021-12-01
Earnings History > 5 > date
2021-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2021-06-30
Earnings History > 6 > report Date
2021-09-17
Earnings History > 6 > date
2021-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2021-03-31
Earnings History > 7 > report Date
2021-04-30
Earnings History > 7 > date
2021-03-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
-
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
0
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2020-09-30
Earnings History > 8 > report Date
2020-12-02
Earnings History > 8 > date
2020-09-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
-
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
0
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2020-06-30
Earnings History > 9 > report Date
2020-09-10
Earnings History > 9 > date
2020-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
-
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2020-03-31
Earnings History > 10 > report Date
2020-06-03
Earnings History > 10 > date
2020-03-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
-
Earnings History > 10 > eps Actual
0
Earnings History > 10 > eps Estimate
-1.3
Earnings History > 10 > eps Difference
1.3
Earnings History > 10 > surprise Percent
100
Earnings History > 11 > period
2019-09-30
Earnings History > 11 > report Date
2019-11-27
Earnings History > 11 > date
2019-09-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
-
Earnings History > 11 > eps Actual
0
Earnings History > 11 > eps Estimate
-0.03
Earnings History > 11 > eps Difference
0.03
Earnings History > 11 > surprise Percent
100
Earnings History > 12 > period
2019-06-30
Earnings History > 12 > report Date
2019-09-30
Earnings History > 12 > date
2019-06-30
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
-
Earnings History > 12 > eps Actual
0
Earnings History > 12 > eps Estimate
-0.05
Earnings History > 12 > eps Difference
0.05
Earnings History > 12 > surprise Percent
100
Earnings History > 13 > period
2019-03-31
Earnings History > 13 > report Date
2019-04-24
Earnings History > 13 > date
2019-03-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
-
Earnings History > 13 > eps Actual
-52.08
Earnings History > 13 > eps Estimate
-0.15
Earnings History > 13 > eps Difference
-51.93
Earnings History > 13 > surprise Percent
-34620
Earnings History > 14 > period
2018-09-30
Earnings History > 14 > report Date
2018-11-28
Earnings History > 14 > date
2018-09-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
-
Earnings History > 14 > eps Actual
-0.13
Earnings History > 14 > eps Estimate
-0.13
Earnings History > 14 > eps Difference
0
Earnings History > 14 > surprise Percent
0
Earnings History > 15 > period
2018-06-30
Earnings History > 15 > report Date
2018-09-27
Earnings History > 15 > date
2018-06-30
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
-
Earnings History > 15 > eps Actual
-64.07
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
-64.07
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2018-03-31
Earnings History > 16 > report Date
2018-05-30
Earnings History > 16 > date
2018-03-31
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
-
Earnings History > 16 > eps Actual
0
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
0
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2017-09-30
Earnings History > 17 > report Date
2017-11-29
Earnings History > 17 > date
2017-09-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
-
Earnings History > 17 > eps Actual
-82.14
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
-82.14
Earnings History > 17 > surprise Percent
-
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AIs BDRX part of any major index - July 2025 Snapshot & Real-Time Chart Breakout Alerts bollywoodhelpline.com
Read more →Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
1/14/2026
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update Defense World
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
STRONG BUY
Target Price:
$178.3005
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Biodexa Pharmaceticals
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-06-30
EPS Actual
-15.06
EPS Estimate
0
EPS Difference
-15.06
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.